
    
      Evaluation of recurrent or metastatic solid tumor patients on Kanitinib single dose and
      continuous multiple dose safety and tolerability, and to determine the maximum tolerated
      Connie imatinib dose (MTD) or the phase II trial recommended dosage.
    
  